KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Acquires $37,812.18 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par bought 4,137 shares of the company's stock in a transaction on Monday, February 10th. The stock was bought at an average cost of $9.14 per share, with a total value of $37,812.18. Following the completion of the acquisition, the insider now owns 5,090,582 shares of the company's stock, valued at $46,527,919.48. This represents a 0.08 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Wednesday, February 12th, Venrock Healthcare Capital Par bought 100,000 shares of KalVista Pharmaceuticals stock. The stock was bought at an average cost of $9.23 per share, with a total value of $923,000.00.
• On Friday, February 7th, Venrock Healthcare Capital Par bought 73,649 shares of KalVista Pharmaceuticals stock. The stock was bought at an average cost of $9.29 per share, with a total value of $684,199.21.
• On Monday, February 3rd, Venrock Healthcare Capital Par bought 14,562 shares of KalVista Pharmaceuticals stock. The stock was bought at an average cost of $9.22 per share, with a total value of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock. The stock was bought at an average cost of $8.76 per share, with a total value of $382,873.32.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV traded up $0.23 during midday trading on Friday, hitting $9.76. 198,408 shares of the company's stock traded hands, compared to its average volume of 304,565. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $16.88. The company has a market cap of $482.34 million, a PE ratio of -2.68 and a beta of 0.85. The firm's fifty day moving average price is $8.75 and its two-hundred day moving average price is $10.54.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last issued its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.01. As a group, equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on KALV shares. Citizens Jmp raised shares of KalVista Pharmaceuticals to a "strong-buy" rating in a research note on Friday, January 31st. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. JMP Securities started coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an "outperform" rating and a $19.00 price target on the stock. TD Cowen started coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating and a $30.00 price target on the stock. Finally, Bank of America assumed coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a "buy" rating and a $22.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, KalVista Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $23.80.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in KALV. Vestal Point Capital LP lifted its holdings in KalVista Pharmaceuticals by 73.9% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company's stock worth $46,320,000 after buying an additional 1,700,000 shares in the last quarter. Boxer Capital Management LLC bought a new stake in shares of KalVista Pharmaceuticals in the 4th quarter worth about $13,467,000. State Street Corp increased its position in shares of KalVista Pharmaceuticals by 68.1% in the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company's stock worth $14,725,000 after purchasing an additional 515,179 shares during the last quarter. Schroder Investment Management Group increased its position in shares of KalVista Pharmaceuticals by 86.8% in the 4th quarter. Schroder Investment Management Group now owns 805,445 shares of the specialty pharmaceutical company's stock worth $6,758,000 after purchasing an additional 374,213 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of KalVista Pharmaceuticals in the 4th quarter worth about $2,268,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).